RT Journal Article
SR Electronic
T1 A rapidly adaptable biomaterial vaccine for SARS-CoV-2
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.07.07.192203
DO 10.1101/2020.07.07.192203
A1 Langellotto, Fernanda
A1 Seiler, Benjamin T.
A1 Yu, Jingyou
A1 Cartwright, Mark J.
A1 White, Des
A1 Yeager, Chyenne
A1 Super, Michael
A1 Doherty, Edward J.
A1 Barouch, Dan H.
A1 Mooney, David J.
YR 2020
UL http://biorxiv.org/content/early/2020/07/07/2020.07.07.192203.abstract
AB The global COVID-19 pandemic motivates accelerated research to develop safe and efficacious vaccines. To address this need, we leveraged a biomaterial vaccine technology that consists of mesoporous silica rods (MSRs) that provide a sustained release of granulocyte-macrophage colony-stimulating factor (GM-CSF) and adjuvants to concentrate and mature antigen-presenting cells at the vaccine site. Here we explored the humoral responses resulting from the use of monophosphoryl lipid A (MPLA) as the adjuvant and SARS-CoV-2 spike proteins S1, S2, the nucleocapsid (N) protein, and receptor binding domain (RBD) as the target antigens. The dose of antigen and impact of pre-manufacturing of vaccines as versus loading antigen just-in-time was explored in these studies. Single shot MSR vaccines induced rapid and robust antibody titers to the presented antigens, even without the use of a boost, and sera from vaccinated animals demonstrated neutralizing activity against a SARS-CoV-2 pseudovirus. Overall, these results suggest the MSR vaccine system may provide potent protective immunity when utilized to present SARS-CoV-2 antigens.Competing Interest StatementThe authors have declared no competing interest.